The Scientist

» drug development and microbiology

Most Recent

image: Maturation of the Infant Microbiome

Maturation of the Infant Microbiome

By | May 13, 2015

Gut microbial communities from breastfed babies are slow to resemble adults’ microbiota.

0 Comments

image: Prokaryotic Microbes with Eukaryote-like Genes Found

Prokaryotic Microbes with Eukaryote-like Genes Found

By | May 6, 2015

Deep-sea microbes possess hallmarks of eukaryotic cells, hinting at a common ancestor for archaea and eukaryotes.

1 Comment

image: Scanning for SIV’s Sanctuaries

Scanning for SIV’s Sanctuaries

By | May 1, 2015

Whole-body immunoPET scans of SIV-infected macaques reveal where the replicating virus hides.  

0 Comments

image: Show Me Your Moves

Show Me Your Moves

By | May 1, 2015

Updated classics and new techniques help microbiologists get up close and quantitative.

0 Comments

image: The Origins of O

The Origins of O

By | May 1, 2015

A strain of HIV that has afflicted more than 100,000 people emerged from gorillas.

0 Comments

image: Bacterial Taxis Deliver Proteins

Bacterial Taxis Deliver Proteins

By | April 28, 2015

Reengineered protein-shuttling machinery can be used to inject a particular protein into mammalian cells, according to a proof-of-principle study.

0 Comments

image: RNA Ebola Drug Clears Animal Study

RNA Ebola Drug Clears Animal Study

By | April 24, 2015

The short interfering RNA-based therapy TKM-Ebola protects monkeys from the viral strain still circulating in West Africa.

0 Comments

image: FDA Calls for Data on ALS Drug

FDA Calls for Data on ALS Drug

By | April 21, 2015

In the midst of a debate about an experimental drug’s early approval, the US Food and Drug Administration requests that full trial results be released.

1 Comment

image: How a Popular Probiotic Works

How a Popular Probiotic Works

By | April 16, 2015

Eating a type of bacterium encourages the activity of other gut microbes, according to a small study.

0 Comments

image: ALS Drug Access Debated

ALS Drug Access Debated

By | April 7, 2015

Biotech company Genervon has requested accelerated approval for its experimental ALS drug after a small but promising Phase 2 trial. Patients advocate for its acceptance, while researchers urge caution.

2 Comments

Popular Now

  1. Trump’s Proposed Budget Would Cut Science Funding
  2. Unstructured Proteins Help Tardigrades Survive Desiccation
  3. Science Advocates Decry Trump’s Proposed Budget
  4. Women Lose Vision After Stem Cell Treatment
Business Birmingham